Biphasic Insulin Lispro Pharmacology 

Biphasic Insulin Lispro
Biphasic Insulin Lispro
Short acting intermediate acting insulin combination.
Short acting intermediate acting insulin combination.
Insulin lispro is a short-acting biosynthetic human insulin analogue. Insulin lispro protamine is an intermediate- acting glucose-lowering agent; it is a suspension of crystals produced from combining insulin lispro and protamine sulfate under appropriate conditions for crystal formation. They are used together for the regulation
of glucose metabolism.
Insulin lispro is a short-acting biosynthetic human insulin analogue. Insulin lispro protamine is an intermediate- acting glucose-lowering agent; it is a suspension of crystals produced from combining insulin lispro and protamine sulfate under appropriate conditions for crystal formation. They are used together for the regulation
of glucose metabolism.
Absorption: The combined product has 2 absorption phases: Early phase represents insulin lispro while the later phase represents the prolonged action of insulin lispro protamine suspension.
Excretion:Renal
Absorption: The combined product has 2 absorption phases: Early phase represents insulin lispro while the later phase represents the prolonged action of insulin lispro protamine suspension.
Excretion:Renal
Absorption: The combined product has 2 absorption phases: Early phase represents insulin lispro while the later phase represents the prolonged action of insulin lispro protamine suspension.
Excretion:Renal
Absorption: The combined product has 2 absorption phases: Early phase represents insulin lispro while the later phase represents the prolonged action of insulin lispro protamine suspension.
Excretion:Renal
18-24 hr.
18-24 hr.
N/A
N/A
Redness, swelling, or itching at the site of inj.
Lipodystrophy, pruritus and rash.
Redness, swelling, or itching at the site of inj.
Lipodystrophy, pruritus and rash.
During episodes of hypoglycemia.
Hypersensitivity
During episodes of hypoglycemia.
Hypersensitivity
1.Dose should be given within 15 minutes before a meal due to the rapid onset of action. 2.Regular monitoring of blood glucose levels and haemoglobin A1c is recommended.
3.Caution when changing insulin as different brands, strength and type of insulin may result in dosage change. 4.Patients with renal or hepatic impairment.
5.Early signs of hypoglycaemia may be different or less obvious in patients with long duration of DM, diabetic
nerve disease, concurrent use of medications e.g. ?-blockers.
1.Dose should be given within 15 minutes before a meal due to the rapid onset of action. 2.Regular monitoring of blood glucose levels and haemoglobin A1c is recommended.
3.Caution when changing insulin as different brands, strength and type of insulin may result in dosage change. 4.Patients with renal or hepatic impairment.
5.Early signs of hypoglycaemia may be different or less obvious in patients with long duration of DM, diabetic
nerve disease, concurrent use of medications e.g. ?-blockers.
Use with caution
Use with caution
N/A
N/A
Use with caution
Use with caution
<18 yr-not recommendesd <18 yr-not recommendesd Treatment of patients with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. Treatment of patients with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.